The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Open accessAbstract
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily. The primary end point in a time-to-event analysis was the first event of clinical failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response. RESULTS: The primary analysis included 500 participants; 253 were assigned to the combination-therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group. A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, respectively, and in 31% of the pooled-monotherapy group (the two monotherapy groups combined). The hazard ratio for the primary end point in the combination-therapy group versus the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001). At week 24, the combination-therapy group had greater reductions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clinical response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P=0.03) and a greater improvement in the 6-minute walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001). The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia. CONCLUSIONS: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clinical-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov number, NCT01178073.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationTreatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationHumbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Self-citationRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
Self-citationDiagnosis and Assessment of Pulmonary Arterial Hypertension
Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.011 · Cited by 1,138
Self-citationBenza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A. E., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-1460 · Cited by 1,104
Self-citationTadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,103
Self-citationGaliè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Self-citationGaliè, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G., Chiossi, E., Kusic-Pajic, A., & Simonneau, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60919-8 · Cited by 920
Self-citationCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Humbert, M., Barst, R. J., Robbins, I. M., Channick, R. N., Galiè, N., Boonstra, A., Rubin, L. J., Horn, E. M., Manes, A., & Simonneau, G. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00028404 · Cited by 640
Self-citationRandomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., & Rubin, L. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-358oc · Cited by 626
Self-citationSimonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00004 · Cited by 616
Self-citationAddition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M., & Seeger, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.027 · Cited by 566
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Self-citationCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Hoeper, M. M., Leuchte, H., Halank, M., Wilkens, H., Meyer, F. J., Seyfarth, H. J., Wensel, R., Ripken, F., Bremer, H., Kluge, S., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00057906 · Cited by 288
Self-citationPrognostic factors of acute heart failure in patients with pulmonary arterial hypertension
Sztrymf, B., Souza, R., Bertoletti, L., Jaïs, X., Sitbon, O., Price, L. C., Simonneau, G., & Humbert, M. (2010) · European Respiratory Journal · doi:10.1183/09031936.00070209 · Cited by 257
Self-citationOutcomes of hospitalisation for right heart failure in pulmonary arterial hypertension
Campo, A., Mathai, S. C., Le Pavec, J., Zaiman, A. L., Hummers, L. K., Boyce, D., Housten, T., Lechtzin, N., Chami, H., Girgis, R. E., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00148310 · Cited by 205
Haddad, F., Peterson, T., Fuh, E., Kudelko, K. T., Pérez, V. D. J., Skhiri, M., Vagelos, R. H., Schnittger, I., Denault, A. Y., Rosenthal, D. N., et al. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.949933 · Cited by 140
Simonneau, G., Rubin, L. J., Galiè, N., Barst, R. J., Fleming, T. R., & Frost, A. (2009) · Annals of Internal Medicine · Cited by 129
Self-citationKemp, K., Savale, L., O’Callaghan, D. S., Jaïs, X., Montani, D., Humbert, M. J. C., Simonneau, G., & Sitbon, O. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.11.002 · Cited by 113
Self-citationAmbrisentan, a Non‐peptide Endothelin Receptor Antagonist
Vatter, H., & Seifert, V. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00063.x · Cited by 67
The role of combination therapy in managing pulmonary arterial hypertension
Ghofrani, H. A., & Humbert, M. J. C. (2014) · European Respiratory Review · doi:10.1183/09059180.00007314 · Cited by 57
Self-citationArif, S. A., & Poon, H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.008 · Cited by 53
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citation
Metadata
- Authors
- Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., Oudiz, R. J., Vonk-Noordegraaf, A., White, R. J., Blair, C., Gillies, H., Miller, K. L., Harris, J. H. N., Langley, J., & Rubin, L. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-27
- Volume
- 373
- Issue
- 9
- Pages
- 834-844
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112229901
- Cited by
- 1,182
- References
- 25
- FWCI
- 87.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.